GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells

Doxorubicin (DOX) is an anticancer drug widely used in oncology, especially for breast cancer. The main limitation of DOX treatment is its cardiotoxicity due to the cumulative dose. Clinically, DOX-induced cardiomyopathy develops as a progressive heart failure caused by a progressive cardiomyocyte’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Dallons, Matthieu, Alpan, Esma, Schepkens, Corentin, Tagliatti, Vanessa, Colet, Jean-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599858/
https://www.ncbi.nlm.nih.gov/pubmed/32992522
http://dx.doi.org/10.3390/cells9102177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599858/
https://www.ncbi.nlm.nih.gov/pubmed/32992522
http://dx.doi.org/10.3390/cells9102177

Ejemplares similares